Varian Medical Systems (NYSE:VAR) is touting a pair of regulatory wins for the next generation of its Vitesse brachytherapy treatment for prostate cancer.
Oncology
BSD launches rectal cancer treatment study
BSD Medical Corp. (NSDQ:BSDM) initiated its Phase I/II HyRec-Trial, evaluating its BSD-2000 Hyperthermia System to treat patients with locally recurrent rectal cancer.
The clinical trial, which has been approved by the German Cancer Society, will enroll 59 patients to evaluate the feasibility and the efficacy of adding hyperthermia to a multimodal treatment regimen, the company said.
China approves Mauna Kea’s CellVizio cancer imaging system
The China State Food & Drug Administration approved Mauna Kea Technologies’ Cellvizio confocal endomicroscopy system, a device design to see cancer faster.
Past repeat CTs may increase breast cancer risk | MassDevice.com On Call
MASSDEVICE ON CALL — Repeated computed tomography testing in the past may increase a woman’s chances of developing breast cancer in the future, according to a new study from the Radiological Society of America.
GE Healthcare wins FDA nod for “breakthrough” FlightPlan for Liver
Healthcare giant GE Healthcare (NYSE:GE) won FDA 510(k) clearance for its liver embolization imaging technology, FlightPlan for Liver.
The system has been on the market in Europe, Latin America and Asia since last year and has already been installed in 10 countries, GE reported.
Sensus lands Health Canada nod for its skin cancer system
Sensus Healthcare landed Health Canada approval for its SRT-100, a therapy device designed to non-surgically treat skin cancer in hospitals and private practice settings.
The SRT-100 system features the company’s SharpBeam characteristics, treating targeted lesions while leaving surrounding healthy tissue intact. The device treats non-melanoma skin cancer, providing virtually pain-free treatment according to the press release.
Seno Medical Instruments raises $15M
Seno Medical Technologies raised $14.5 million in an equity round from 28 unnamed investors, according to a regulatory filing.
The San Antonio, Texas-based medical device company is developing opto-acoustic imaging technology to locate cancerous tumors in breast tissue.
Delcath’s cancer-treating system lands U.S., Australian regulatory wins
Medical device company Delcath Systems (NSDQ:DCTH) is on a roll, notching a couple new regulatory milestones this month for its organ-isolating ChemoSat chemotherapy treatment systems.
Cancer research: Varian awards $100k for radiation therapy registry
Varian Medical Systems (NYSE:VAR), a medical device and software manufacturer focused on radiation-based cancer treatment, awarded a $100,000 grant to the American Board of Radiology Foundation to support a national brachytherapy registry.
How the past has influenced the future of breast cancer care
By: Patricia Keegan, M.D.
I have been with FDA for more than 20 years and an oncologist for 30 years. During this time, I have witnessed an evolving change in our understanding of cancer. We once viewed cancer as a single disease, such as breast or lung cancer. Today we understand that most cancers that arise in a single organ or area of the body are often a genetically diverse group of cancers that have different patterns of spread, different rates of growth, and different responsiveness to treatment.
IBM’s Watson supercomputer learns about cancer | MassDevice.com On Call
MASSDEVICE ON CALL — IBM’s Watson supercomputer, which trounced a pair of human competitors on Jeopardy more than year ago, has begun treating patients at the Memorial Sloan-Kettering Cancer Center.
A result of a partnership announced earlier this year, Watson is "in the trenches" with oncologists to analyze cancer research and literature to provide diagnostic and treatment solutions.